![David Alastair Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Alastair Smith
Presidente presso
THERACRYF PLC
Patrimonio netto: 2 M $ in data 30/06/2026
Profilo
David Alastair MacLaughlin Smith was the founder of Avacta Group Plc, founded in 2004, where the title held was Chief Executive Officer & Executive Director from 2005 to 2024.
Current jobs include Non-Executive Chairman at SPARTA Biodiscovery Ltd., Non-Executive Chairman at TheraCryf Plc starting in 2025, and Independent Non-Executive Director at Thalia Therapeutics Plc starting in 2025.
Former jobs include Chief Executive Officer & Director at Avacta Life Sciences Ltd., Director-Institute of Molecular Biophysics at the University of Leeds, and Director at TheraGenetics Ltd. Education includes undergraduate and doctorate degrees from The University of Manchester.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
AVACTA GROUP PLC 0,33% | 04/06/2025 | 1.565.100 ( 0,33% ) | 2 M $ | 30/06/2026 |
THERACRYF PLC 0,19% | 31/03/2025 | 4.000.000 ( 0,19% ) | 11 400 $ | 30/06/2026 |
Posizioni attive di David Alastair Smith
| Società | Posizione | Inizio |
|---|---|---|
| THALIA THERAPEUTICS PLC | Direttore/Membro del Consiglio | 08/01/2025 |
| THERACRYF PLC | Presidente | 19/02/2025 |
Sparta Biodiscovery Ltd.
 Sparta Biodiscovery Ltd. Medical SpecialtiesHealth Technology Manufactures instruments for chemical analysis and pharmaceutical research | Presidente | - |
Precedenti posizioni note di David Alastair Smith
| Società | Posizione | Fine |
|---|---|---|
| AVACTA GROUP PLC | Fondatore | 01/05/2024 |
Avacta Life Sciences Ltd.
 Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Amministratore Delegato | - |
TheraGenetics Ltd.
 TheraGenetics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures brachytherapy seeds for prostate and localized cancers | Direttore/Membro del Consiglio | - |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formazione di David Alastair Smith
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
49
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
Evgen Pharma Plc
 Evgen Pharma Plc Medical/Nursing ServicesHealth Services Engages in the development of pharmaceutical products and focus on cancer & neurological disease | Health Services |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
TheraGenetics Ltd.
TheraGenetics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures brachytherapy seeds for prostate and localized cancers | Health Technology |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
N4 Pharma Plc
 N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Sparta Biodiscovery Ltd.
Sparta Biodiscovery Ltd. Medical SpecialtiesHealth Technology Manufactures instruments for chemical analysis and pharmaceutical research | Health Technology |
